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Pregnancy is associated with an increased risk of thrombosis
in women with mechanical prosthetic heart valves (MPHV)
(1). Effective anticoagulation therapy is, therefore, critical
but remains challenging because both oral anticoagulants
and heparins may be associated with important maternal
and fetal complications (1,2).
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Warfarin, a time-honored treatment for nonpregnant
patients with MPHV has been also shown to be effective in
the prevention of thromboembolic complications during
pregnancy (1–3). Exposure to warfarin in the first 6 to 12
weeks of pregnancy, however, can be associated with a
significant risk to the fetus, including spontaneous abortions
and warfarin embryopathy (1,3). In addition, the use of oral
anticoagulation therapy during pregnancy may also be
associated with fetal hemorrhage, including intracranial
bleeding (4), central nervous system abnormalities, and
minor neurologic dysfunction and low intelligent quotients
in later age (1). Although a number of recent studies have
reported no untoward effects with the use of warfarin during
pregnancy (5–7), others have clearly shown a high and
unacceptable rate of fetal complications (8–13). Because of
these risks, both women and physicians have been reluctant
to use oral anticoagulation during the first trimester or at
any time during pregnancy.
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contents of this paper to disclose.Is warfarin-related fetal risk dose dependent? Vitale et al.
(12) in 1999 suggested a close relationship between warfarin
dosage and fetal complications in pregnant women with
MPHV. These investigators studied 58 pregnancies and
showed that the majority of fetal complications were related
to warfarin dose of 5 mg per day. Thirty-three gestations
in women taking 5 mg were associated with 28 healthy
babies (82%) in comparison to 22 fetal complications (fetal
loss 76%, warfarin embryopathy 8%) in 25 women treated
with 5 mg daily. The same group of investigators (11)
ater reported poor outcome in 30 of 71 pregnancies (fetal
oss in 28 cases, and embryopathy in 2 cases). Multivariable
nalysis identified warfarin at daily dose 5 mg as a
ignificant predictor (p 0.001) of poor fetal outcome. This
information resulted in a recommendation to consider the
use of oral anticoagulation throughout pregnancy when
warfarin dose is 5 mg daily by the recently published
European Society of Cardiology guidelines (14) for the
management of women with heart disease in pregnancy.
In this issue of the Journal, De Santo et al. (15) report
additional 16 pregnancies in women who received therapeu-
tic anticoagulation with a daily warfarin dose 5 mg before
an aortic valve replacement and later received a new-
generation MPHV. These patients, who continued to
receive low-dose warfarin throughout pregnancy with very
close follow-up, had no thromboembolic or hemorrhagic
complications, and all had healthy babies. Patients were
carefully monitored with weekly international normalized
ratio (INR) determinations targeted by the investigators to
be between 1.5 and 2.5.
Although these results are encouraging, they suffer from
important limitations and, therefore, can have only limited
clinical impact at the present time. The findings can be
applied only to patients with new-generation aortic MPHV
adequately anticoagulated with low-dose oral anticoagula-
tion. In addition, as indicated by the investigators, the
combined number of patients included in their 3 publica-
tions (11,12,15) is small and cannot be considered conclu-
sive. A further concern is that, in spite of the absolute safety
reported in the study by De Santo et al. (15), the results are
not supported by other publications describing fetal com-
plications with low-dose warfarin. Sadler et al. (10) reported
7 miscarriages in 11 women treated with 5 mg warfarin
daily compared to 5 miscarriages in 11 women treated with
5 mg daily. Shannon et al. (9) reported spontaneous
abortion in 8 of 10 women receiving warfarin during the
first trimester; 6 of these were treated with 5 mg per day
and the other 2 received 6 mg. In addition, 1 case of
warfarin embryopathy was associated with a warfarin dose of
5 to 6 mg per day. McLintock et al. (16) reported 2 perinatal
deaths and 2 stillbirths as a result of fetal intracerebral
hemorrhage in women taking warfarin at daily doses of 4
mg and 5 mg, respectively, and an infant death due to
warfarin embryopathy in a woman taking 6 mg per day until
week 34. Mehndiratta et al. (13) reported a case of severe
rmalize
rin.
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treated with warfarin 3 mg per day throughout pregnancy.
De Santo et al. (15) used a relatively low INR goal
between 1.5 and 2.5 on the basis of recent studies showing
a low incidence of thromboembolic events among nonpreg-
nant patients with new-generation MPHV (17,18). Because
pregnant patients were not included in these studies, the
safety of this approach for pregnancy remains unproven. For
this reason, and until more data are available, it seems
advisable to follow the American College of Cardiology/
American Heart Association guidelines (19) and use a
warfarin dose during pregnancy aiming to achieve an INR
level of 2.5 even in patients with new-generation MPHV
in the aortic position.
Another limitation associated with the protocol presented
by De Santo et al. (15) is a mandatory cesarean section
delivery in all patients. Although relatively safe, a cesarean
delivery is associated with a substantial increase in short-
and long-term risks, including surgery-related infections,
bleeding, thromboembolism, pain, and damage to pelvic
organs, and later, increased risk of miscarriage, ectopic
gestation, placenta previa, and placenta accreta (20).
Because of the remaining concern regarding fetal effects
of warfarin, recent guidelines recommendations to use low-
dose warfarin, if therapeutically effective, throughout preg-
nancy (14) seem premature and require further validation.
The only patient reported by De Santo et al. (15) to have
valve thrombosis was treated with low-molecular-weight
heparin at a dose titrated to achieve peak anti-Xa levels of
0.7 to 1.2 IU/ml, as recommended by recent guidelines
(14,19). These guidelines, however, ignore the manufac-
turer recommendations to monitor both peak and trough
levels (21). The importance of measuring trough levels was
first demonstrated by Barbour et al. (22), who evaluated 138
peak and 112 trough anti-Xa levels in 13 pregnancies and
found only 9% of trough levels at 0.5 IU/ml. Even when
peak levels were between 0.75 IU/ml and 1.0 IU/ml, only
15% of trough levels were 0.5 IU/ml. These findings were
later confirmed by Friedrich and Hameed (23), who studied
15 pregnant subjects receiving therapeutic doses of enoxa-
parin given twice daily. While all peak levels at 3 to 4 h were
Our Recommended Approach to Anticoagulation Therapy for WomeTable 1 Our Recommended Approach to Anticoagulation Thera
Higher Risk
Old-Generation MPHV in Mitral Position, MPHV in Tricuspid Position,
Atrial Fibrillation, History of TE on Heparin
N
Warfarin (INR 2.5 to 3.5) for 35 to 36 weeks followed by IV UFH (aPTT
2.5) to parturition  ASA 81 to 100 mg/day
LM
OR
LMWH SQ Q12 h (trough anti-Xa 0.7 IU/ml, peak anti-Xa 1.5 IU/ml) or
UFH SQ Q12 h or IV* (mid interval aPTT 2.5) for 12 weeks, followed
by warfarin (INR: 2.5 to 3.5) to 35 to 36 weeks, then UFH IV
(aPTT 2.5) to parturition  ASA 81 to 100 mg/day.
LM
*IV preffered.
aPTT activated partial thromboplastin time; ASA acetylsalicylic acid; INR international no
heart valve; Q  every; SQ  subcutaneous; TE  thromboembolism; UFH  unfractionated hepabetween 0.5 IU/ml and 1.0 IU/ml, 20% at 8 h and 73% at12 h were subtherapeutic. The relationship between 177
paired peak and trough levels of anti-Xa during pregnancy
were further studied by our group (24); in 26 pregnant
patients receiving adjusted-dose enoxaparin given every
12 h, peak levels of 0.7 to 1.2 IU/ml were associated with
subtherapeutic trough level (0.6 IU/ml) in 50% of the
cases, and only 7 (6%) determinations, 6 of them with
trough levels 0.8 IU/ml, had peak levels 1.5 IU/ml.
These data, in addition to documented risk of valve throm-
bosis with subtherapeutic pre-dose anti-Xa levels (2), sup-
port the importance of routine measurement and mainte-
nance of trough levels at therapeutic range in pregnant
women with MPHV (0.6 IU/ml in lower risk women,
and 0.7 IU/ml in high-risk women) (Table 1) (25). Peak
levels should also be monitored to detect excessive antico-
agulation (i.e., anti-Xa1.5 IU/ml), which requires switch-
ing to 8-hourly dosing.
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